Squarepoint Ops LLC raised its position in shares of Stevanato Group S.p.A. (NYSE:STVN – Free Report) by 65.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,302 shares of the company’s stock after purchasing an additional 6,853 shares during the quarter. Squarepoint Ops LLC’s holdings in Stevanato Group were worth $317,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. increased its stake in Stevanato Group by 54.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock valued at $84,000 after purchasing an additional 1,086 shares in the last quarter. Hilltop National Bank grew its stake in shares of Stevanato Group by 34.3% in the second quarter. Hilltop National Bank now owns 4,395 shares of the company’s stock worth $81,000 after acquiring an additional 1,122 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in shares of Stevanato Group in the first quarter worth approximately $241,000. Harbor Capital Advisors Inc. grew its stake in shares of Stevanato Group by 109.1% in the second quarter. Harbor Capital Advisors Inc. now owns 8,867 shares of the company’s stock worth $163,000 after acquiring an additional 4,626 shares during the period. Finally, Hardy Reed LLC bought a new stake in shares of Stevanato Group in the first quarter worth approximately $321,000.
Stevanato Group Stock Performance
Shares of NYSE STVN opened at €19.00 ($20.88) on Friday. The firm has a market capitalization of $5.62 billion, a price-to-earnings ratio of 34.55, a price-to-earnings-growth ratio of 8.36 and a beta of 0.57. The firm has a 50 day moving average of €19.96 and a 200 day moving average of €21.75. The company has a current ratio of 1.74, a quick ratio of 1.13 and a debt-to-equity ratio of 0.19. Stevanato Group S.p.A. has a 12-month low of €16.56 ($18.20) and a 12-month high of €35.56 ($39.08).
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on STVN. Morgan Stanley reduced their price target on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Citigroup reduced their price target on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of €29.25 ($32.14).
Read Our Latest Analysis on Stevanato Group
Stevanato Group Company Profile
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Recommended Stories
- Five stocks we like better than Stevanato Group
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- 3 Fintech Stocks With Good 2021 Prospects
- 4 Quirky ETFs With Big Potential for Impressive Gains
Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVN – Free Report).
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.